Company intelligence / Profile preview

ViroXis

Ownership: Private
Development stage: Phase 2

Overview

ViroXis develops innovative botanical pharmaceuticals derived from East Indian Sandalwood Oil, focusing initially on a topical ointment for treating common skin warts caused by HPV. The company leverages the long history of sandalwood oil in traditional medicine for various infectious conditions. No published results from late-stage clinical trials are available.

Therapeutic areas: Infectious Diseases
Modalities: Botanical pharmaceuticalsNatural product-derived therapeutics (from sandalwood oil)
Industry: Biotech

Drug pipeline

1 asset

Albuterpenoid

Phase 2

Indications: Skin warts

Beyond the preview

Go deeper on ViroXis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ViroXis.

Explore the full profile